메뉴 건너뛰기




Volumn 40, Issue 1, 2014, Pages 62-73

Efficacy of aripiprazole for the treatment of schizophrenia: What dose is required?;Efficacité de l'aripiprazole dans le traitement de la schizophrénie: quelle dose pour quel effet?

Author keywords

Aripiprazole; Dose; Effect; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; DOSE; EFFECT; EFFET; SCHIZOPHRENIA; SCHIZOPHRÉNIE;

EID: 84894473301     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.encep.2013.12.002     Document Type: Article
Times cited : (4)

References (46)
  • 1
    • 33748354488 scopus 로고    scopus 로고
    • Metabolic profiling of CSF: Evidence that early intervention may impact on disease progression and outcome in schizophrenia
    • E. Holmes, T.M. Tsang, and J.T. Huang et al. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia PLoS Med 3 8 2006 e327
    • (2006) PLoS Med , vol.3 , Issue.8 , pp. 327
    • Holmes, E.1    Tsang, T.M.2    Huang, J.T.3
  • 2
    • 84858705903 scopus 로고    scopus 로고
    • Pharmacotherapy challenges in patients with first-episode psychosis
    • A. Abdel-Baki, C. Ouellet-Plamondon, and A. Malla Pharmacotherapy challenges in patients with first-episode psychosis J Affect Disord 138 Suppl. 2012 S3 S14
    • (2012) J Affect Disord , vol.138 SUPPL.
    • Abdel-Baki, A.1    Ouellet-Plamondon, C.2    Malla, A.3
  • 3
    • 39949085594 scopus 로고    scopus 로고
    • World psychiatric association pharmacopsychiatry section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia
    • R. Tandon, R.H. Belmaker, and W.F. Gattaz et al. World psychiatric association pharmacopsychiatry section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia Schizophr Res 100 1-3 2008 20 38
    • (2008) Schizophr Res , vol.100 , Issue.13 , pp. 20-38
    • Tandon, R.1    Belmaker, R.H.2    Gattaz, W.F.3
  • 4
    • 0033850147 scopus 로고    scopus 로고
    • Depression in schizophrenia: Perspective in the era of "atypical" antipsychotic agents
    • S.G. Siris Depression in schizophrenia: perspective in the era of "atypical" antipsychotic agents Am J Psychiatry 157 9 2000 1379 1389
    • (2000) Am J Psychiatry , vol.157 , Issue.9 , pp. 1379-1389
    • Siris, S.G.1
  • 5
    • 0037177358 scopus 로고    scopus 로고
    • The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor
    • S. Jordan, V. Koprivica, and R. Chen et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor Eur J Pharmacol 441 3 2002 137 140
    • (2002) Eur J Pharmacol , vol.441 , Issue.3 , pp. 137-140
    • Jordan, S.1    Koprivica, V.2    Chen, R.3
  • 6
    • 6044224986 scopus 로고    scopus 로고
    • Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile
    • T. Hirose, Y. Uwahodo, and S. Yamada et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile J Psychopharmacol 18 3 2004 375 383
    • (2004) J Psychopharmacol , vol.18 , Issue.3 , pp. 375-383
    • Hirose, T.1    Uwahodo, Y.2    Yamada, S.3
  • 7
    • 60349086480 scopus 로고    scopus 로고
    • A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia
    • S. Leucht, K. Komossa, and C. Rummel-Kluge et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia Am J Psychiatry 166 2 2009 152 163
    • (2009) Am J Psychiatry , vol.166 , Issue.2 , pp. 152-163
    • Leucht, S.1    Komossa, K.2    Rummel-Kluge, C.3
  • 11
    • 32644442073 scopus 로고    scopus 로고
    • Pharmacologie et mode d'action des neuroleptiques
    • N. Franck, and F. Thibaut Pharmacologie et mode d'action des neuroleptiques EMC - Psychiatrie 2 4 2005 282 299
    • (2005) EMC - Psychiatrie , vol.2 , Issue.4 , pp. 282-299
    • Franck, N.1    Thibaut, F.2
  • 12
    • 33644747716 scopus 로고    scopus 로고
    • Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study
    • A.F. Christensen, J. Poulsen, and C.T. Nielsen et al. Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study Acta Psychiatr Scand 113 2 2006 148 153
    • (2006) Acta Psychiatr Scand , vol.113 , Issue.2 , pp. 148-153
    • Christensen, A.F.1    Poulsen, J.2    Nielsen, C.T.3
  • 13
    • 84866487775 scopus 로고    scopus 로고
    • Effects of antipsychotic medications on quality of life and psychosocial functioning in patients with early-stage schizophrenia: 1-year follow-up naturalistic study
    • X. Guo, Z. Zhang, and J. Zhai et al. Effects of antipsychotic medications on quality of life and psychosocial functioning in patients with early-stage schizophrenia: 1-year follow-up naturalistic study Compr Psychiatry 53 7 2012 1006 1012
    • (2012) Compr Psychiatry , vol.53 , Issue.7 , pp. 1006-1012
    • Guo, X.1    Zhang, Z.2    Zhai, J.3
  • 14
    • 78651226362 scopus 로고    scopus 로고
    • Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder
    • P. Blier, and C. Blondeau Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder J Affect Disord 128 Suppl. 1 2011 S3 S10
    • (2011) J Affect Disord , vol.128 , Issue.SUPPL. 1
    • Blier, P.1    Blondeau, C.2
  • 15
    • 44849110854 scopus 로고    scopus 로고
    • Dosing atypical antipsychotics
    • A. Cutler, S. Ball, and S.M. Stahl Dosing atypical antipsychotics CNS Spectr 13 5 Suppl. 9 2008 1 16
    • (2008) CNS Spectr , vol.13 , Issue.5 SUPPL. 9 , pp. 1-16
    • Cutler, A.1    Ball, S.2    Stahl, S.M.3
  • 16
    • 25144456112 scopus 로고    scopus 로고
    • Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    • J.A. Lieberman, T.S. Stroup, and J.P. McEvoy et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 353 12 2005 1209 1223
    • (2005) N Engl J Med , vol.353 , Issue.12 , pp. 1209-1223
    • Lieberman, J.A.1    Stroup, T.S.2    McEvoy, J.P.3
  • 17
    • 59049088231 scopus 로고    scopus 로고
    • Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia
    • B.J. Kinon, V.L. Stauffer, and S. Kollack-Walker et al. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia J Clin Psychopharmacol 28 6 2008 601 607
    • (2008) J Clin Psychopharmacol , vol.28 , Issue.6 , pp. 601-607
    • Kinon, B.J.1    Stauffer, V.L.2    Kollack-Walker, S.3
  • 18
    • 33846852409 scopus 로고    scopus 로고
    • Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: A randomized, double-blind, placebo-controlled trial
    • T.K. Tran-Johnson, D.A. Sack, and R.N. Marcus et al. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial J Clin Psychiatry 68 1 2007 111 119
    • (2007) J Clin Psychiatry , vol.68 , Issue.1 , pp. 111-119
    • Tran-Johnson, T.K.1    Sack, D.A.2    Marcus, R.N.3
  • 19
    • 33748659860 scopus 로고    scopus 로고
    • Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: A double-blind, placebo-controlled comparison with intramuscular haloperidol
    • R. Andrezina, R.C. Josiassen, and R.N. Marcus et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol Psychopharmacology (Berl) 188 3 2006 281 292
    • (2006) Psychopharmacology (Berl) , vol.188 , Issue.3 , pp. 281-292
    • Andrezina, R.1    Josiassen, R.C.2    Marcus, R.N.3
  • 20
    • 84873660725 scopus 로고    scopus 로고
    • Aripiprazole versus olanzapine in the treatment of schizophrenia: A clinical study from india
    • K.C. Jindal, G.P. Singh, and V. Munjal Aripiprazole versus olanzapine in the treatment of schizophrenia: a clinical study from india Int J Psychiatry Clin Pract 17 1 2013 21 29
    • (2013) Int J Psychiatry Clin Pract , vol.17 , Issue.1 , pp. 21-29
    • Jindal, K.C.1    Singh, G.P.2    Munjal, V.3
  • 21
    • 55749106241 scopus 로고    scopus 로고
    • A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia
    • R.L. Findling, A. Robb, and M. Nyilas et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia Am J Psychiatry 165 11 2008 1432 1441
    • (2008) Am J Psychiatry , vol.165 , Issue.11 , pp. 1432-1441
    • Findling, R.L.1    Robb, A.2    Nyilas, M.3
  • 22
    • 33846860210 scopus 로고    scopus 로고
    • Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in chinese patients with risperidone as an active control: A randomized trial
    • H.Y. Chan, W.W. Lin, and S.K. Lin et al. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in chinese patients with risperidone as an active control: a randomized trial J Clin Psychiatry 68 1 2007 29 36
    • (2007) J Clin Psychiatry , vol.68 , Issue.1 , pp. 29-36
    • Chan, H.Y.1    Lin, W.W.2    Lin, S.K.3
  • 23
    • 34547870543 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia
    • J.P. McEvoy, D.G. Daniel, and W.H. Carson et al. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia J Psychiatr Res 41 11 2007 895 905
    • (2007) J Psychiatr Res , vol.41 , Issue.11 , pp. 895-905
    • McEvoy, J.P.1    Daniel, D.G.2    Carson, W.H.3
  • 24
    • 33749020011 scopus 로고    scopus 로고
    • The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia
    • [quiz: 719]
    • A.J. Cutler, R.N. Marcus, and S.A. Hardy et al. The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia CNS Spectr 11 9 2006 691 702 [quiz: 719]
    • (2006) CNS Spectr , vol.11 , Issue.9 , pp. 691-702
    • Cutler, A.J.1    Marcus, R.N.2    Hardy, S.A.3
  • 25
    • 0038488945 scopus 로고    scopus 로고
    • Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder
    • S.G. Potkin, A.R. Saha, and M.J. Kujawa et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder Arch Gen Psychiatry 60 7 2003 681 690
    • (2003) Arch Gen Psychiatry , vol.60 , Issue.7 , pp. 681-690
    • Potkin, S.G.1    Saha, A.R.2    Kujawa, M.J.3
  • 26
    • 0036738786 scopus 로고    scopus 로고
    • Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder
    • J.M. Kane, W.H. Carson, and A.R. Saha et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder J Clin Psychiatry 63 9 2002 763 771
    • (2002) J Clin Psychiatry , vol.63 , Issue.9 , pp. 763-771
    • Kane, J.M.1    Carson, W.H.2    Saha, A.R.3
  • 27
    • 84872535465 scopus 로고    scopus 로고
    • The neurocognitive effects of aripiprazole compared with risperidone in the treatment of schizophrenia
    • G. Sato, S. Yoshimura, and H. Yamashita et al. The neurocognitive effects of aripiprazole compared with risperidone in the treatment of schizophrenia Hiroshima J Med Sci 61 4 2012 75 83
    • (2012) Hiroshima J Med Sci , vol.61 , Issue.4 , pp. 75-83
    • Sato, G.1    Yoshimura, S.2    Yamashita, H.3
  • 28
    • 65449123582 scopus 로고    scopus 로고
    • A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia
    • J.M. Kane, O. Osuntokun, and L.A. Kryzhanovskaya et al. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia J Clin Psychiatry 70 4 2009 572 581
    • (2009) J Clin Psychiatry , vol.70 , Issue.4 , pp. 572-581
    • Kane, J.M.1    Osuntokun, O.2    Kryzhanovskaya, L.A.3
  • 29
    • 0141828595 scopus 로고    scopus 로고
    • Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: A placebo-controlled 26-week study
    • T.A. Pigott, W.H. Carson, and A.R. Saha et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study J Clin Psychiatry 64 9 2003 1048 1056
    • (2003) J Clin Psychiatry , vol.64 , Issue.9 , pp. 1048-1056
    • Pigott, T.A.1    Carson, W.H.2    Saha, A.R.3
  • 30
    • 9144237416 scopus 로고    scopus 로고
    • Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia
    • S. Kasper, M.N. Lerman, and R.D. McQuade et al. Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia Int J Neuropsychopharmacol 6 4 2003 325 337
    • (2003) Int J Neuropsychopharmacol , vol.6 , Issue.4 , pp. 325-337
    • Kasper, S.1    Lerman, M.N.2    McQuade, R.D.3
  • 31
    • 60349130296 scopus 로고    scopus 로고
    • A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia
    • W.W. Fleischhacker, R.D. McQuade, and R.N. Marcus et al. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia Biol Psychiatry 65 6 2009 510 517
    • (2009) Biol Psychiatry , vol.65 , Issue.6 , pp. 510-517
    • Fleischhacker, W.W.1    McQuade, R.D.2    Marcus, R.N.3
  • 32
    • 34249306913 scopus 로고    scopus 로고
    • Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations
    • D.G. Daniel, G.W. Currier, and D.L. Zimbroff et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations J Psychiatr Pract 13 3 2007 170 177
    • (2007) J Psychiatr Pract , vol.13 , Issue.3 , pp. 170-177
    • Daniel, D.G.1    Currier, G.W.2    Zimbroff, D.L.3
  • 33
    • 33751247015 scopus 로고    scopus 로고
    • Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: Sub-analysis of a double-blind study
    • R. Andrezina, R.N. Marcus, and D.A. Oren et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study Curr Med Res Opin 22 11 2006 2209 2219
    • (2006) Curr Med Res Opin , vol.22 , Issue.11 , pp. 2209-2219
    • Andrezina, R.1    Marcus, R.N.2    Oren, D.A.3
  • 34
    • 34249729541 scopus 로고    scopus 로고
    • Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: A post-hoc analysis of 4 randomized, placebo-controlled clinical trials
    • S.R. Marder, B. West, and G.S. Lau et al. Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post-hoc analysis of 4 randomized, placebo-controlled clinical trials J Clin Psychiatry 68 5 2007 662 668
    • (2007) J Clin Psychiatry , vol.68 , Issue.5 , pp. 662-668
    • Marder, S.R.1    West, B.2    Lau, G.S.3
  • 35
    • 77249147515 scopus 로고    scopus 로고
    • Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: Post-hoc analysis of randomized clinical trial data
    • A.S. Robb, W.H. Carson, and M. Nyilas et al. Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post-hoc analysis of randomized clinical trial data J Child Adolesc Psychopharmacol 20 1 2010 33 38
    • (2010) J Child Adolesc Psychopharmacol , vol.20 , Issue.1 , pp. 33-38
    • Robb, A.S.1    Carson, W.H.2    Nyilas, M.3
  • 36
    • 79955895316 scopus 로고    scopus 로고
    • Aripiprazole versus haloperidol treatment in early-stage schizophrenia
    • R.R. Girgis, D.B. Merrill, and S.R. Vorel et al. Aripiprazole versus haloperidol treatment in early-stage schizophrenia J Psychiatr Res 45 6 2011 756 762
    • (2011) J Psychiatr Res , vol.45 , Issue.6 , pp. 756-762
    • Girgis, R.R.1    Merrill, D.B.2    Vorel, S.R.3
  • 37
    • 77954142170 scopus 로고    scopus 로고
    • Effect of aripiprazole versus haloperidol on PANSS prosocial items in early-episode patients with schizophrenia
    • J.P. Docherty, R.A. Baker, and J. Eudicone et al. Effect of aripiprazole versus haloperidol on PANSS prosocial items in early-episode patients with schizophrenia Schizophr Res 120 1-3 2010 199 203
    • (2010) Schizophr Res , vol.120 , Issue.13 , pp. 199-203
    • Docherty, J.P.1    Baker, R.A.2    Eudicone, J.3
  • 38
    • 70149093748 scopus 로고    scopus 로고
    • Comparative utility of aripiprazole and haloperidol in schizophrenia: Post-hoc analysis of two 52-week, randomized, controlled trials
    • J.M. Kane, E. Kim, and H.J. Kan et al. Comparative utility of aripiprazole and haloperidol in schizophrenia: post-hoc analysis of two 52-week, randomized, controlled trials Appl Health Econ Health Policy 7 2 2009 109 119
    • (2009) Appl Health Econ Health Policy , vol.7 , Issue.2 , pp. 109-119
    • Kane, J.M.1    Kim, E.2    Kan, H.J.3
  • 39
    • 63349093738 scopus 로고    scopus 로고
    • Aripiprazole for patients with schizophrenia and schizoaffective disorder: An open-label, randomized, study versus haloperidol
    • I.R. de Oliveira, H. Elkis, and W.F. Gattaz et al. Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol CNS Spectr 14 2 2009 93 102
    • (2009) CNS Spectr , vol.14 , Issue.2 , pp. 93-102
    • De Oliveira, I.R.1    Elkis, H.2    Gattaz, W.F.3
  • 40
    • 34447117847 scopus 로고    scopus 로고
    • A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients schizophrenia trial of aripiprazole: (STAR) study
    • R. Kerwin, B. Millet, and E. Herman et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients schizophrenia trial of aripiprazole: (STAR) study Eur Psychiatry 22 7 2007 433 443
    • (2007) Eur Psychiatry , vol.22 , Issue.7 , pp. 433-443
    • Kerwin, R.1    Millet, B.2    Herman, E.3
  • 41
    • 84873840061 scopus 로고    scopus 로고
    • Comparison of long-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: A trial using equipoise-stratified randomization
    • H. Jin, P.A. Shih, and S. Golshan et al. Comparison of long-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization J Clin Psychiatry 74 1 2013 10 18
    • (2013) J Clin Psychiatry , vol.74 , Issue.1 , pp. 10-18
    • Jin, H.1    Shih, P.A.2    Golshan, S.3
  • 42
    • 3242659711 scopus 로고    scopus 로고
    • Dose response and atypical antipsychotics in schizophrenia
    • B.J. Kinon, J. Ahl, and V.L. Stauffer et al. Dose response and atypical antipsychotics in schizophrenia CNS Drugs 18 9 2004 597 616
    • (2004) CNS Drugs , vol.18 , Issue.9 , pp. 597-616
    • Kinon, B.J.1    Ahl, J.2    Stauffer, V.L.3
  • 43
    • 84894490600 scopus 로고    scopus 로고
    • Aripiprazole: résumé des caractéristiques du produit
    • Aripiprazole: résumé des caractéristiques du produit, http://www.has-sante.fr/portail/jcms/c-400137/fr/abilify
  • 44
    • 77952974468 scopus 로고    scopus 로고
    • International consensus study of antipsychotic dosing
    • D.M. Gardner, A.L. Murphy, and H. O'Donnell et al. International consensus study of antipsychotic dosing Am J Psychiatry 167 6 2010 686 693
    • (2010) Am J Psychiatry , vol.167 , Issue.6 , pp. 686-693
    • Gardner, D.M.1    Murphy, A.L.2    O'Donnell, H.3
  • 45
    • 84864408922 scopus 로고    scopus 로고
    • World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance
    • A. Hasan, P. Falkai, and T. Wobrock et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance World J Biol Psychiatry 13 5 2012 318 378
    • (2012) World J Biol Psychiatry , vol.13 , Issue.5 , pp. 318-378
    • Hasan, A.1    Falkai, P.2    Wobrock, T.3
  • 46
    • 80755135527 scopus 로고    scopus 로고
    • Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia
    • S.K. Lin, C.K. Chen, and Y.L. Liu Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia J Clin Psychopharmacol 31 6 2011 758 762
    • (2011) J Clin Psychopharmacol , vol.31 , Issue.6 , pp. 758-762
    • Lin, S.K.1    Chen, C.K.2    Liu, Y.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.